@article {Moses:2010:1027-3719:197,
title = "Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi",
journal = "The International Journal of Tuberculosis and Lung Disease",
parent_itemid = "infobike://iuatld/ijtld",
publishercode ="iuatld",
year = "2010",
volume = "14",
number = "2",
publication date ="2010-02-01T00:00:00",
pages = "197-202",
itemtype = "ARTICLE",
issn = "1027-3719",
eissn = "1815-7920",
url = "https://www.ingentaconnect.com/content/iuatld/ijtld/2010/00000014/00000002/art00012",
keyword = "tuberculosis, rifampicin, HIV, nevirapine, Malawi, alanine transferase",
author = "Moses, M. and Zachariah, R. and Tayler-Smith, K. and Misinde, D. and Foncha, C. and Manzi, M. and Bauerfeind, A. and Mwagomba, B. and Kwanjana, J. and Harries, A. D.",
abstract = "SETTING: Thyolo District Hospital, rural Malawi.OBJECTIVES: To report on 1) clinical, immunological and virological outcomes and 2) safety among human immunodeficiency virus (HIV) infected patients with tuberculosis (TB) who received concurrent nevirapine (NVP) and rifampicin (RMP) based treatment.DESIGN: Retrospective cohort study.METHODS: Analysis of programme data, JuneDecember 2007.RESULTS: Of a total of 156 HIV-infected TB patients who started NVP-based antiretroviral treatment, 136 (87%) completed TB treatment successfully, 16 (10%) died and 5 (4%) were transferred out. Mean body weight and CD4 gain (adults) were respectively 4.4 kg (95%CI 3.35.4) and 140 cells/mm3 (95%CI 117162). Seventy-four per cent of patients who completed TB treatment and had a viral load performed (n = 74) had undetectable levels (CONCLUSIONS: In a rural district in Malawi, concomitant NVP and RMP treatment is associated with good TB treatment outcomes and appears safe. Further follow-up of patients would be useful to ascertain the longer-term effects of this concurrent treatment.",
}